FREEZE-DRIED PLATELET PRODUCT FOR THE TREATMENT OF TRAUMA-ASSOCIATED BLOOD LOSS IN CANINES

The OPMED is conducting market research to identify technologies that meet requirements for the development of a freeze-dried platelet product for the treatment of trauma-associated blood loss in canines. This market research may also assist with the further development and/or refinement of the requirements. 

Military Working Dogs (MWDs) play a critical role in protecting human lives and supporting military objectives in the operational environment. MWDs work in close conjunction with their handlers and Service Members and are exposed to the same combat trauma threats and similar non-battle injury risks, and thus canine blood or blood components are indicated for appropriate treatment. 

The OPMED has a requirement to develop, deliver, and field safe and effective Canine Blood Products (CBP) for the treatment of traumatic hemorrhage. The CBP program is using a Family of Systems (FoS) approach that aims to develop multiple medical materiel solutions that are most relevant for use in austere environments where medical products and evacuation may be limited. 
This RFI seeks responses to the canine freeze-dried platelet component of this FoS only. 

North American Industry Classification System (NAICS) Code: Unknown.

RFI Attachments: The following documents are attached to the RFI:                                                                                                              A02-RFI for Freeze Dried Platelet Canine 
       Attachment 1: Technology Readiness Levels (TRLs) (Reference Only)
       Attachment 2: Company & Product Information

Response Due Date: Interested parties shall submit the RFI response electronically by 2:00pm Eastern on March 2, 2026, via e-mail to:
 

Katherine Ramsburg via email at: katherine.j.ramsburgciv@health.mil      

Email Subject/title: "RFI response for HT9427-26-RF